Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Natalia Reoutova, 07 Jan 2020

A prospective cohort study of mothers taking antiepileptic drugs (AEDs) and their breastfed infants has found substantially lower AED concentrations in infant vs maternal blood, with nearly half of all obtained AED concentrations in nursing infants being less than the lower limit of quantification (LLoQ).

6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Cyclosporine emulsion holds potential in vernal keratoconjunctivitis

07 Jan 2020

Use of cyclosporine A cationic emulsion (CsA CE) 0.1% eye drops in the treatment of patients with severe active vernal keratoconjunctivitis (VKC) is safe and yields improvements in keratitis, symptoms and quality of life (QoL) that are maintained for up to 8 months, according to the results of a trial.

The trial initially randomized 169 patients (age range, 4–17 years) in the 4-month VEKTIS study, among whom 142 entered the 8-month follow-up period. During the follow-up, CsA CE-treated patients remained on their original regimen—CsA CE four times daily (QID, high-dose) or CsA CE twice daily (BID, low-dose) plus vehicle BID—while vehicle-treated patients were allocated to one of these two active regimens.

Compared with those in the vehicle group, patients in the CsA CE groups showed greater improvements in main efficacy measures, including corneal fluorescein staining (CFS) score rescue medication use, key VKC symptoms (photophobia, tearing, itching and mucous discharge), and QoL (assessed by QUICK questionnaire) during the 4-month evaluation period.

The improvements observed with CsA CE remained stable over the 8-month follow-up, with the beneficial effects on most efficacy measures consistently greater with the high-dose regimen.

CsA CE had a favourable safety profile. Overall, treatment-related, treatment-emergent adverse events occurred in 15 (20.8 percent) and 11 (15.7 percent) of the CsA CE high-dose and low-dose patients, respectively. The most frequently reported event was instillation site pain (13.9 percent and 7.1 percent, respectively).

Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Natalia Reoutova, 07 Jan 2020

A prospective cohort study of mothers taking antiepileptic drugs (AEDs) and their breastfed infants has found substantially lower AED concentrations in infant vs maternal blood, with nearly half of all obtained AED concentrations in nursing infants being less than the lower limit of quantification (LLoQ).

6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.